Generic Name and Formulations:
Isosorbide dinitrate 40mg; sust-rel caps.
- Hybrid Minimally Invasive Esophagectomy Confers Lower Complication Rate
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- Oral Calcium Channel Blockers Chart
- Mood Disorder Treatments
- Esophageal and Esophagogastric Junction Cancer Treatment Regimens
Indications for DILATRATE-SR:
Prophylaxis and treatment of angina. Not for acute attacks.
See full labeling. Allow at least an 18-hour interval daily between doses to avoid development of tolerance. Max 160mg/day.
Concomitant PDE inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) or riociguat.
Recent MI. CHF. Volume depletion. Hypotension. Hypertrophic cardiomyopathy. Monitor standing blood pressure when increasing doses. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypotension potentiated with alcohol, other vasodilators.
Headache, transient lightheadedness, orthostatic hypotension; rare: syncope, angina, rebound hypertension.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer